Home  »  News   »  Who are the Institutional Holders in Novo Nordisk ...

Who are the Institutional Holders in Novo Nordisk A/S (NVO)?

Novo Nordisk A/S (NYSE: NVO) is 14.94% higher on its value in year-to-date trading and has touched a low of $47.24 and a high of $68.71 in the current 52-week trading range. The NVO stock was last observed hovering at around $66.53 in the last trading session, with the day’s gains setting it 0.72% off its average median price target of $70.02 for the next 12 months. It is also 18.74% off the consensus price target high of $82.76 offered by 29 analysts, but current levels are -47.45% lower than the price target low of $45.61 for the same period.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Currently trading at $67.25, the stock is 2.42% and 4.43% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.92 million and changing 1.08% at the moment leaves the stock 14.35% off its SMA200. NVO registered 29.99% gain for a year compared to 6-month gain of 15.38%. The firm has a 50-day simple moving average (SMA 50) of $64.78 and a 200-day simple moving average (SMA200) of $61.08.

The stock witnessed a 4.94% loss in the last 1 month and extending the period to 3 months gives it a 25.48%, and is -0.28% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.57% over the week and 1.85% over the month.

Novo Nordisk A/S (NVO) has around 43158 employees, a market worth around $118.08B and $19.03B in sales. Current P/E ratio is 25.94 and Fwd P/E is 21.94. Profit margin for the company is 31.90%. Distance from 52-week low is 42.34% and -2.13% from its 52-week high. The company has generated returns on investments over the last 12 months (69.10%).

Novo Nordisk A/S (NVO) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Novo Nordisk A/S (NVO) is a “Overweight”. 29 analysts offering their recommendations for the stock have an average rating of 2.30, where 9 rate it as a Hold and 2 think it is a “Overweight”. 14 of the analysts rate the stock as a “Buy”. 3 analysts have rated the stock as a Sell or Underperform.

Novo Nordisk A/S is expected to release its quarterly report on 08/06/2020 and quarterly earnings per share for the current quarter are estimated at $0.67 with sales reaching $4.63B over the same period.The EPS is expected to grow by 2.80% this year, but quarterly earnings will post 6.30% year-over-year. Quarterly sales are estimated to grow 2.40% in year-over-year returns.

Novo Nordisk A/S (NVO) Top Institutional Holders

729 institutions hold shares in Novo Nordisk A/S (NVO), with 211.39k shares held by insiders accounting for 0.01% while institutional investors hold 9.48% of the company’s shares. The shares outstanding are 2.35B, and float is at 1.17B with Short Float at 0.19%. Institutions hold 9.48% of the Float.

The top institutional shareholder in the company is Renaissance Technologies, LLC with over 27.86 million shares valued at $1.68 billion. The investor’s holdings represent 1.54% of the NVO Shares outstanding. As of Mar 30, 2020, the second largest holder is Loomis Sayles & Company, LP with 16.43 million shares valued at $989.31 million to account for 0.91% of the shares outstanding. The other top investors are Fisher Asset Management, LLC which holds 15.33 million shares representing 0.85% and valued at over $922.57 million, while Bank of America Corporation holds 0.58% of the shares totaling 10.48 million with a market value of $630.64 million.

Novo Nordisk A/S (NVO): Who are the competitors?

The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 36.12% up over the past 12 months. Bristol-Myers Squibb Company (BMY) is 26.20% up on the 1-year trading charts. Short interest in the company’s stock has risen 34.4% from the last report on May 14, 2020 to stand at a total of 2.25 million short shares sold with a short interest ratio of 1.97.

Related Posts




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam